Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis

• Published in: Europace (London, England) Vol. 25; no. 3; pp. 1077 - 1086
• Main Authors: Kaza, Nandita, Htun, Varanand, Miyazawa, Alejandra, Simader, Florentina, Porter, Bradley, Howard, James P, Arnold, Ahran D, Naraen, Akriti, Luria, David, Glikson, Michael, Israel, Carsten, Francis, Darrel P, Whinnett, Zachary I, Shun-Shin, Matthew J, Keene, Daniel
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 30.03.2023
• Subjects: Cardiac Conduction System Disease - therapy; Cardiac Pacing, Artificial - adverse effects; Cardiac Resynchronization Therapy - adverse effects; Heart Conduction System; Heart Failure - diagnosis; Heart Failure - therapy; Humans; Pacemaker, Artificial; Review; Stroke Volume - physiology; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Physiological pacing; Biventricular pacing; Upgrade; Conduction system pacing
• ISSN: 1099-5129; 1532-2092; 1532-2092
• DOI: 10.1093/europace/euac188

Abstract Guidelines recommend patients undergoing a first pacemaker implant who have even mild left ventricular (LV) impairment should receive biventricular or conduction system pacing (CSP). There is no corresponding recommendation for patients who already have a pacemaker. We conducted a meta-analysis of randomized controlled trials (RCTs) and observational studies assessing device upgrades. The primary outcome was the echocardiographic change in LV ejection fraction (LVEF). Six RCTs (randomizing 161 patients) and 47 observational studies (2644 patients) assessing the efficacy of upgrade to biventricular pacing were eligible for analysis. Eight observational studies recruiting 217 patients of CSP upgrade were also eligible. Fourteen additional studies contributed data on complications (25 412 patients). Randomized controlled trials of biventricular pacing upgrade showed LVEF improvement of +8.4% from 35.5% and observational studies: +8.4% from 25.7%. Observational studies of left bundle branch area pacing upgrade showed +11.1% improvement from 39.0% and observational studies of His bundle pacing upgrade showed +12.7% improvement from 36.0%. New York Heart Association class decreased by −0.4, −0.8, −1.0, and −1.2, respectively. Randomized controlled trials of biventricular upgrade found improvement in Minnesota Heart Failure Score (−6.9 points) and peak oxygen uptake (+1.1 mL/kg/min). This was also seen in observational studies of biventricular upgrades (−19.67 points and +2.63 mL/kg/min, respectively). In studies of the biventricular upgrade, complication rates averaged 2% for pneumothorax, 1.4% for tamponade, and 3.7% for infection over 24 months of mean follow-up. Lead-related complications occurred in 3.3% of biventricular upgrades and 1.8% of CSP upgrades. Randomized controlled trials show significant physiological and symptomatic benefits of upgrading pacemakers to biventricular pacing. Observational studies show similar effects between biventricular pacing upgrade and CSP upgrade.